Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial

BACKGROUND: The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ(9)-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex(®)) can dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Trigo, Jose M., Soliman, Alexandra, Quilty, Lena C., Fischer, Benedikt, Rehm, Jürgen, Selby, Peter, Barnes, Allan J., Huestis, Marilyn A., George, Tony P., Streiner, David L., Staios, Gregory, Le Foll, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791962/
https://www.ncbi.nlm.nih.gov/pubmed/29385147
http://dx.doi.org/10.1371/journal.pone.0190768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791962/
https://www.ncbi.nlm.nih.gov/pubmed/29385147
http://dx.doi.org/10.1371/journal.pone.0190768

Ejemplares similares